AMPLY DISCOVERY EXPLAINS HOW ITS AI TECHNOLOGY CAN IDENTIFY NOVEL BIOLGICAL DRUG CANDITATES

CEO, Ben Thomas, and CCO, Dermot Tierney, joined Moira Gunn from BioTech Nation to discuss exactly why the company was formed and how, with the assistance of AI and machine learning, it’s technology can identify novel biological drug and nutraceutical candidates

Click here to listen.

Podcast taken from: https://www.biotechnation.com/episodes/why-do-ai-one-way-when-you-can-do-it-25-dr-ben-thomas-and-dermot-tierny-ceo-cco-amply-discovery

Share the Post:

Related Posts

In Memory of Dr Alan Mawson

It is with great sadness that Clarendon marks the passing of Alan, a colleague, mentor and friend to so many across our firm and the wider venture capital community in Northern Ireland. Over 25 years he shaped not only Clarendon, but the careers and lives of countless people who had the privilege of working with him.

Read More